Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in advanced clear-cell renal cell carcinoma with ECOG performance status 2
2011-001211-31Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in clear cell renal cell carcinoma (ccRCC), sponsored by University of Birmingham. Primary endpoints: Primary tolerability and Primary efficacy. Started Jan 2012; status: completed.
02
Drugs
pazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2011-001211-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001211-31.